(12) United States Patent (10) Patent No.: US 9,506.065 B2 Croce Et Al
Total Page:16
File Type:pdf, Size:1020Kb
USOO9506065B2 (12) United States Patent (10) Patent No.: US 9,506.065 B2 Croce et al. (45) Date of Patent: Nov. 29, 2016 (54) DIAGNOSIS AND TREATMENT OF (2013.01); C12N 23 10/31 (2013.01); C12N CANCERS WITH MICRORNA LOCATED IN 23.10/32 (2013.01); C12N 23.10/33 (2013.01); OR NEAR CANCER-ASSOCATED CI2O 2600/106 (2013.01); C12O 2600/158 CHROMOSOMAL FEATURES (2013.01); C12O 2600/178 (2013.01) (58) Field of Classification Search (71) Applicant: Thomas Jefferson University, CPC ............................. A61K 48/00; C12N 15/113 Philadelphia, PA (US) See application file for complete search history. (72) Inventors: Carlo M. Croce, Columbus, OH (US); Chang-Gong Liu, Pearland, TX (US); (56) References Cited George A. Calin, Pearland, TX (US); Cinzia Sevignani, Philadelphia, PA U.S. PATENT DOCUMENTS (US) 7,723,030 B2 5, 2010 Croce et al. 8,778,676 B2 7/2014 Croce et al. (73) Assignee: Thomas Jefferson University, 2008/0261908 A1 10/2008 Croce et al. Philadelphia, PA (US) 2008/0306006 A1 12/2008 Croce et al. 2008/0306017 A1 12/2008 Croce et al. (*) Notice: Subject to any disclaimer, the term of this 2008/0306018 A1 12/2008 Croce et al. patent is extended or adjusted under 35 2010/0203544 A1 8, 2010 Croce et al. U.S.C. 154(b) by 2 days. (Continued) (21) Appl. No.: 14/846,193 FOREIGN PATENT DOCUMENTS (22) Filed: Sep. 4, 2015 WO WO O3,O29459 4/2003 WO WO O3,O29459 A2 4/2003 (65) Prior Publication Data (Continued) US 2015/0368647 A1 Dec. 24, 2015 OTHER PUBLICATIONS Related U.S. Application Data Amendment After Allowance dated Feb. 2, 2010, U.S. Appl. No. 11/194,055. “Diagnosis and Treatment of Cancers With MicroRNA (60) Division of application No. 14/281,756, filed on May Located in or Near Cancer-Associated Chromosomal Features.” 19, 2014, now Pat. No. 9,150,859, which is a continuation of application No. 13/972,759, filed on (Continued) Aug. 21, 2013, now Pat. No. 8,778,676, which is a division of application No. 12/767,279, filed on Apr. 26, 2010, now abandoned, which is a continuation of Primary Examiner — Amy Bowman application No. 11/194,055, filed on Jul. 29, 2005, (74) Attorney, Agent, or Firm — Hamilton, Brook, Smith now Pat. No. 7,723,030, which is a & Reynolds, P.C. continuation-in-part of application No. PCT/US2005/004865, filed on Feb. 9, 2005. (57) ABSTRACT (60) Provisional application No. 60/543,119, filed on Feb. 9, 2004, provisional application No. 60/542,929, filed MicroRNA genes are highly associated with chromosomal on Feb. 9, 2004, provisional application No. features involved in the etiology of different cancers. The 60/542,963, filed on Feb. 9, 2004, provisional perturbations in the genomic structure or chromosomal application No. 60/542,940, filed on Feb. 9, 2004, architecture of a cell caused by these cancer-associated provisional application No. 60/580,959, filed on Jun. chromosomal features can affect the expression of the miR 18, 2004, provisional application No. 60/580,797, gene(s) located in close proximity to that chromosomal filed on Jun. 18, 2004. feature. Evaluation of miR gene expression can therefore be used to indicate the presence of a cancer-causing chromo (51) Int. Cl. Somal lesion in a Subject. As the change in miR gene C7H 2L/02 (2006.01) expression level caused by a cancer-associated chromo C7H 2L/04 (2006.01) Somal feature may also contribute to cancerigenesis, a given A6 IK 4.8/00 (2006.01) cancer can be treated by restoring the level of miR gene CI2N IS/IT3 (2010.01) expression to normal. microRNA expression profiling can be CI2O I/68 (2006.01) used to diagnose cancer and predict whether a particular A6 IK3I/7088 (2006.01) cancer is associated with an adverse prognosis. The identi A6 IK3I/73 (2006.01) fication of specific mutations associated with genomic A6 IK 45/06 (2006.01) regions that harbor miR genes in CLL patients provides a (52) U.S. Cl. means for diagnosing CLL and possibly other cancers. CPC ....... CI2N 15/1135 (2013.01); A61 K3I/7088 (2013.01); A61 K3I/713 (2013.01); A61 K 45/06 (2013.01); C12N 15/113 (2013.01); 15 Claims, 9 Drawing Sheets CI2O I/6886 (2013.01); C12N 23 10/11 (6 of 9 Drawing Sheet(s) Filed in Color) US 9,506.065 B2 Page 2 (56) References Cited Bartel, D. P. “MicroRNAs. Genomics, Biogenesis, Mechanism, and Function.” Cell, 116(2):281-297 (Jan. 2004). U.S. PATENT DOCUMENTS Birren, B., et al., Homo sapiens chromosome 17, clone hRPC. 1073 F 15, complete sequence, GenBank Accession No. 2011/OO525O2 A1 3/2011 Croce et al. AC004686.1 online), Oct. 1998 retrieved on Apr. 23, 2014). 2014/0256040 A1 9, 2014 Croce et al. Retrieved from the Internet URL: www.ncbi.nlm.nih.gov/nuccore? ACOO46861 FOREIGN PATENT DOCUMENTS Calin, G. A., et al., “A MicroRNA Signature Associated with WO WO 2004/043387 A2 5, 2004 Prognosis and Progression in Chronic Lymphocytic Leukemia,” N. WO WO 2005/O13901 A2 2, 2005 Engl. J. Med., 353 (17): 1793-1801 (Oct. 2005). Calin, G. A., et al., “Frequent Deletions and Down-Regulation of Micro-RNA Genes miR15 and miR16 at 13c, 14 in Chronic OTHER PUBLICATIONS Lymphocytic Leukemia,” Proc. Natl. Acad. Sci. USA, 99 (24): 15524-15529 (Oct. 2002). Notice of Non-Compliant Amendment (37 CFR 1.121) dated Oct. 7, Calin, G. A. et al., “Human MicroRNA Genes are Frequently 2009, U.S. Appl. No. 11/194,055, "Diagnosis and Treatment of Located at Fragile Sites and Genomic Regions Involved in Can Cancers With MicroRNA Located in or Near Cancer-Associated cers.” Proc. Natl. Acad. Sci. USA, 101 (9):2999-3004 (Mar. 2004). Chromosomal Features.” Calin, G. A., et al., “MicroRNA Profiling Reveals Distinct Signa Office Action dated Jun. 13, 2012, U.S. Appl. No. 12/751,463, tures in B Cell Chronic Lymphocytic Leukemias.” Proc. Natl. Acad. “Diagnosis and Treatment Of Cancers With MicroRNA Located in Sci. USA, 101 (32): 11755-11760 (Jun. 2004). or Near Cancer Associated Chromosomal Features.” Chen et al., “Micro-RNA-21 regulates the sensitivity to cisplatin in Office Action dated Mar. 18, 2009, U.S. Appl. No. 11/194,055, human neuroblastoma cells,” J. Pediatr. Surg. 47(10): 1797-1805 “Diagnosis and Treatment of Cancers With MicroRNA Located in (2012). or Near Cancer-Associated Chromosomal Features.” Cheung, et al., “Natural variation in human gene expression Reply dated Jul. 16, 2009, U.S. Appl. No. 11/194,055. “Diagnosis assessed in lymphoblastoid cells,” Nature Genetics, 2003, vol. 33. and Treatment Of Cancers With MicroRNA Located in or Near p. 422. Cancer-Associated Chromosomal Features.” Cobb, et al., “Sepsis gene expression profiling: Murine splenic Reply to Restriction Requirement dated Dec. 16, 2008, U.S. Appl. compared with hepatic responses determined by using complemen No. 11/194,055, "Diagnosis and Treatment of Cancers With MicroRNA Located in or Near Cancer-Associated Chromosomal tary DNA microarrays.” Crit Care Med. 2002, vol. 30, p. 2711. Features. Communication Pursuant to Article 94(3) EPC dated Dec. 13, 2007. Reply to Restriction Requirement dated Jul. 7, 2008, U.S. Appl. No. Application No. EP 05 723130.0, "Diagnosis and Treatment of 11/194,055, "Diagnosis and Treatment of Cancers With MicroRNA Cancers With MicroRna Located in or Near Cancer-Associated Located in or Near Cancer-Associated Chromosomal Features.” Chromosomal Features.” Reply to Restriction Requirement dated Mar. 5, 2008, U.S. Appl. Esquela-Kerscher, A., et al. “Oncomirs—microRNAs with a role in No. 11/194,055, "Diagnosis and Treatment of Cancers With cancer,” Nat Rev Cancer, 6(4): 259-269 (Apr. 2006). MicroRNA Located in or Near Cancer-Associated Chromosomal European Search Report and Written Opinion dated Apr. 12, 2012, Features. Application No. EP 10 17 9994, "Diagnosis and Treatment of Restriction Requirement dated Feb. 13, 2012, U.S. Appl. No. Cancers With MicroRna Located in or Near Cancer-Associated 12,751,463, “Diagnosis and Treatment of Cancers With MicroRNA Chromosomal Features.” Located in or Near Cancer Associated Chromosomal Features.” Examination Report dated Apr. 12, 2013, Application No. EP 1017 Restriction Requirement dated May 23, 2008, U.S. Appl. No. 9994, "Diagnosis and Treatment of Cancers With MicroRna 11/194,055. “Diagnosis and Treatment of Cancers With MicroRNA Located in or Near Cancer-Associated Chromosomal Features.” Located in or Near Cancer-Associated Chromosomal Features.” Fabbri et al., “MicroRNAs bind to Toll-like receptors to induce Restriction Requirement dated Sep. 20, 2007 U.S. Appl. No. prometastatic inflammatory response.” PNAS 109(31): E2110 11/194,055. “Diagnosis and Treatment of Cancers With MicroRNA E2116 (2012). Located in or Near Cancer-Associated Chromosomal Features.” Fabbri, M. and R. Garzon, “Implications of MicroRNAs in Normal Supplemental Amendment dated Oct. 15, 2009.U.S. Appl. No. Hematopoiesis and Human Leukemia,” Clinical Leukemia, 2.96 11/194,055. “Diagnosis and Treatment of Cancers With MicroRNA 101 (May 2008). Located in or Near Cancer-Associated Chromosomal Features.” Fei, J., et al., “Inhibitory effects of anti-miRNA oligonucleotides Petition Decision for U.S. Appl. No. 14/281,756, "Diagnosis and (AMOs) on A549 cell growth.” J. Drug Target 16(9): 688-693 Treatment of Cancers With MicroRNA Located in or Near Cancer (2008). Associated Chromosomal Features', date of mailing Sep. 2, 2015. Ferracin, M., et al., “MicroRNAs involvement infludarabine refrac Notice of Allowance for U.S. Appl. No. 14/281,756, "Diagnosis and tory chronic lymphocytic leukemia,” Molecular Cancer, 9:123, 14 Treatment of Cancers With MicroRNA Located in or Near Cancer pages (2010), doi:10.1186/1476-4598-9-123.